



NCCN Guidelines: Recurrence Risk in Basal Cell Carcinoma¹

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/TPR40](https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf)

PeerView
Oncology



Low Risk

High Risk

Any High-Risk Factor Places the Patient in a High-Risk Category

Trunk, extremities <2 cm

Location

- Trunk, extremities <2 cm
- Cheeks, forehead, scalp, neck, and pretibia any size
- “Mask areas” of face

Well defined

Borders

Poorly defined

Primary

Primary vs recurrent

Recurrent

(-)

Immunosuppression

(+)

(-)

Site of prior RT

(+)

Pathology

Nodular, superficial

Subtype

Aggressive growth pattern

(-)

Perineural involvement

(+)

1. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf.



PRACTICE AID

Principles of Systemic Therapy for laBCC or mBCC

Full abbreviations, accreditation, and disclosure information available at [PeerView.com/TPR40](https://www.peerview.com/TPR40)

PeerView
Oncology



Consider systemic therapy in la/mBCC, but not in settings where topical treatment, surgery, or RT is likely to be curative (eg, recurrent local disease not amenable to surgery/RT, nodal or distant metastases)¹

Multidisciplinary discussion to determine best treatment approach and rule out surgery or radiation



Hh inhibitors

- Drug holidays can be used to address toxicity and improve adherence and QoL
- **Sonidegib**: for the treatment of adult patients with laBCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy²
- **Vismodegib**: for the treatment of adults with mBCC, or with laBCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation³



Cemiplimab⁴

- For the treatment of patients with laBCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate
- For the treatment of patients with mBCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate

1. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf.

2. Odomzo (sonidegib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205266s004lbl.pdf.

3. Erivedge (vismodegib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf.

4. Libtayo (cemiplimab-rwlc) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf.